These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2011-001023-21 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients with Type II Hyperlipidemia Studio randomizzato, in doppi... 2012-04-10 due-trials
Completed, but no date, and reported results 2012-002302-43 A study to investigate the analgesic effects of buprenorphine and milnacipram in healthy volunteers. bad-data
Reported results 2015-004765-90 A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks 2016-11-21 due-trials
Completed, but no date 2015-005486-23 A Multi-center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of DFD-04 (itraconazole) Ointment, 5% in Patients with Inflammatory L... bad-data
Completed, but no date, and reported results Terminated 2016-003197-41 A Multi-Center, Randomized, Double-Blind, Parallel-Group, Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Le... bad-data
Completed, but no date, and reported results 2017-000262-30 Efficacy, Safety, Tolerability and Pharmacokinetics of EXN-32 and EXN-44 in patients with Parkinson¿s Disease experiencing motor fluctuations Efficacy, Safety, Tolerability and Pharmacokinetics of ... bad-data
Listed as ongoing, but also has a completion date 2018-004223-36 A Randomised, Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) with MabThera® in Subjects with Previously Unt... 2023-02-27 bad-data
Reported results 2019-002810-37 A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued ... 2022-04-20 due-trials
Completed, report not yet due 2021-005382-40 A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment... 2023-05-15 not-yet-due